Analysts Issue Forecasts for Context Therapeutics Inc.’s Q2 2023 Earnings (NASDAQ:CNTX)

Posted by Defense World Staff on May 19th, 2023

Context Therapeutics Inc. (NASDAQ:CNTX – Get Rating) – Investment analysts at Diamond Equity reduced their Q2 2023 earnings per share estimates for shares of Context Therapeutics in a report released on Monday, May 15th. Diamond Equity analyst H. Diamond now expects that the company will post earnings per share of ($0.17) for the quarter, down from their prior estimate of ($0.16). The consensus estimate for Context Therapeutics’ current full-year earnings is ($1.17) per share. Diamond Equity also issued estimates for Context Therapeutics’ Q3 2023 earnings at ($0.20) EPS, Q4 2023 earnings at ($0.22) EPS, FY2023 earnings at ($0.99) EPS, Q1 2024 earnings at ($0.23) EPS, Q2 2024 earnings at ($0.27) EPS, Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.31) EPS and FY2024 earnings at ($1.09) EPS.

Separately, HC Wainwright downgraded shares of Context Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, March 23rd.

Context Therapeutics Stock Up 2.5 %

Shares of NASDAQ CNTX opened at $0.56 on Thursday. The company has a market cap of $8.94 million, a PE ratio of -0.50 and a beta of 2.27. The firm’s 50-day moving average price is $0.60 and its 200-day moving average price is $0.81. Context Therapeutics has a 52-week low of $0.47 and a 52-week high of $2.52.

Institutional Investors Weigh In On Context Therapeutics

Large investors have recently made changes to their positions in the company. Affinity Asset Advisors LLC purchased a new position in shares of Context Therapeutics in the first quarter worth approximately $1,687,000. Worth Venture Partners LLC boosted its stake in shares of Context Therapeutics by 81.6% during the 1st quarter. Worth Venture Partners LLC now owns 317,729 shares of the company’s stock worth $689,000 after acquiring an additional 142,762 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Context Therapeutics during the 3rd quarter valued at $145,000. swisspartners Ltd. increased its stake in shares of Context Therapeutics by 111.8% in the 4th quarter. swisspartners Ltd. now owns 180,000 shares of the company’s stock worth $119,000 after purchasing an additional 95,000 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in Context Therapeutics in the 3rd quarter worth $80,000. 25.88% of the stock is currently owned by institutional investors.

About Context Therapeutics

(Get Rating)

Context Therapeutics Inc, a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers.